Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Vaccine-induced tissue resident memory T cells and antibodies synergize to prevent mucosal HIV infection [CITE-seq]

ABSTRACT: Vaccine-induced tissue resident memory T cells and antibodies synergize to prevent mucosal HIV infection [CITE-seq]

PROVIDER: PRJNA574940 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10202603_1.fastq.gz	Fastqsanger.gz
	SRR10202603_2.fastq.gz	Fastqsanger.gz
	SRR10202604_1.fastq.gz	Fastqsanger.gz
	SRR10202604_2.fastq.gz	Fastqsanger.gz
	SRR10202605_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 56

Similar Datasets

Vaccine-induced tissue resident memory T cells and antibodies synergize to prevent mucosal HIV infection [CITE-seq]

Project description:This study measures single cell RNA and protein expression in Gag stimulated and non-stimulated vaginal tissue from four SIV-protected rhesus macaques.

2020-03-05 | GSE138156 | GEO

Titration of 124 antibodies using CITE-Seq on human PBMCs

Project description:Single-cell RNA-sequencing (scRNA-Seq) is widely used to characterize immune cell populations. However, mRNA levels correlate poorly with expression of surface proteins, which are well established to define immune cell types. CITE-Seq (cellular indexing of transcriptomes and epitopes by sequencing) utilizes oligonucleotide-tagged antibodies to simultaneously analyze surface phenotypes and transcriptomes. Considering the high costs of adding surface phenotyping to scRNA-Seq, we aimed to determine which of 188 tested CITE-Seq antibodies can detect their antigens on human peripheral blood mononuclear cells (PBMCs), a commonly interrogated cell population in immunology, and find the optimal concentration for staining. The recommended concentration was optimal for 76 antibodies, whereas staining quality of 7 antibodies improved when the concentration was doubled. 33 and 8 antibodies still worked well when the concentration was reduced to 1/5 or 1/25, respectively. 64 antigens were not detected at any antibody concentration. Optimizing the antibody panel by removing antibodies not able to detect their target antigens and adjusting concentrations of the remaining antibodies could enable a cost reduction of almost 50%. In conclusion, our data are a resource for building an informative and cost-effective panel of CITE-Seq antibodies and use them at their optimal concentrations in future CITE-seq experiments on human PBMCs.

2022-09-18 | GSE213282 | GEO

Titration of 124 antibodies using CITE-Seq on human PBMCs

Project description:Titration of 124 antibodies using CITE-Seq on human PBMCs

| PRJNA880327 | ENA

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

Project description:Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

| PRJNA909824 | ENA

Strategies for optimizing CITE-seq for human islets and other tissues

Project description:Defining the immunological landscape of human tissue is an important area of research, but challenges include the impact of tissue disaggregation on cell phenotypes and the low abundance of immune cells in many tissues. Here, we describe methods to troubleshoot and standardize Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITE-seq) for studies involving enzymatic digestion of human tissue. We tested epitope susceptibility of 92 antibodies commonly used to differentiate immune lineages and cell states on human peripheral blood mononuclear cells following treatment with an enzymatic digestion cocktail used to isolate islets. We observed CD4, CD8a, CD25, CD27, CD120b, CCR4, CCR6, and PD1 display significant sensitivity to enzymatic treatment, effects that often could not be overcome with alternate antibodies. Comparison of flow cytometry-based CITE-seq antibody titrations and sequencing data supports that for the majority of antibodies, flow cytometry accurately predicts optimal antibody concentrations for CITE-seq. Comparison by CITE-seq of immune cells in enzymatically digested islet tissue and donor- matched spleen not treated with enzymes revealed little digestion-induced epitope cleavage, suggesting increased sensitivity of CITEseq and/or that the islet structure may protect resident immune cells from enzymes. Within islets, CITEseq identified immune cells difficult to identify by transcriptional signatures alone, such as distinct tissue-resident T cell subsets, mast cells, and innate lymphoid cells (ILCs). Collectively this study identifies strategies for the rational design and testing of CITE-seq antibodies for single-cell studies of immune cells within islets and other tissues.

2023-02-12 | GSE224767 | GEO

Decoy Antibodies Block Extracellular HSP70, Prevent Self Signaling and Inhibit Melanoma Cell Survival

Project description:Decoy Antibodies Block Extracellular HSP70, Prevent Self Signaling and Inhibit Melanoma Cell Survival

| PRJNA1422219 | ENA

Costimulatory CD28 bispecific antibodies synergize with conventional and targeted chemotherapy to elicit potent anti-tumor responses.

Project description:Costimulatory bispecific antibodies (TAAxCD28) designed to cluster tumor-associated antigens (TAA) on tumor cells to CD28 receptor on T cells represent a significant innovation in immunotherapy, offering transformative opportunities for combination strategies to combat treatment-resistant cancers. Here, we demonstrate for the first time that TAAxCD28 bispecifics synergize with both conventional and targeted chemotherapy agents to significantly enhance antitumor efficacy in humanized murine tumor models. Mechanistically, an EGFRxCD28 bispecific, when combined with 5-fluorouracil (5-FU). Promotes the expansion and clonal diversification of tumor-infiltrating effector CD8+ T cells, which associates with markedly improved tumor growth control and survival benefit. Further, the combination therapy reprograms the immunosuppressive tumor microenvironment, by rewiring suppressive tumor myeloid cells to immunostimulatory phenotypes, upregulating costimulatory molecules, and increasing the expression of intratumoral proinflammatory cytokines and chemokines. Additionally, we show that a novel HER2xCD28 bispecific antibody, in combination with Trastuzumab-deruxtecal (Tras-Dxd, Enhertu) – an emerging front-line cancer cell-targeted antibody drug conjugate (ADC) – elicits potent tumor clearance, also by expanding and increasing the clonal diversity of tumor infiltrating effector CD8+ T cells. Collectively, our findings highlight a previously underexplored potential of CD28 costimulatory bispecific antibodies to deliver a highly effective combination strategy alongside frontline chemotherapies and ADCs, thereby expanding therapeutic options for hard-to-treat malignancies and supporting their advancement into clinical application.

2026-09-08 | GSE317150 | GEO

Costimulatory CD28 bispecific antibodies synergize with conventional and targeted chemotherapy to elicit potent anti-tumor responses

2026-09-08 | GSE306914 | GEO

Costimulatory CD28 bispecific antibodies synergize with conventional and targeted chemotherapy to elicit potent anti-tumor responses.

Project description:Costimulatory CD28 bispecific antibodies synergize with conventional and targeted chemotherapy to elicit potent anti-tumor responses.

| PRJNA1406175 | ENA

Costimulatory CD28 bispecific antibodies synergize with conventional and targeted chemotherapy to elicit potent anti-tumor responses II

2026-09-08 | GSE330851 | GEO